Peak Bio

Closed (deSPAC)

Profile in progress

What it is: Bio Co., Ltd
What it’s doing now: Merging with Ignyte Acquisition Corp. (IGNY) — closed (despac).
What you should know: Data is still being assembled for this company — what is shown below is everything we have verified so far.

The business, per its filings

SEC primary

Bio Co., Ltd. Peak Bio Co., Ltd. is a clinical-stage biopharmaceutical company focused on developing therapeutics addressing significant unmet needs in the areas of oncology and inflammation. Peak Bios management team has a combined 50 years of industry experience in the areas of small molecules, antibodies, and antibody-drug-conjugates (ADC), forging successful companies that create best-in-class therapeutics. Peak Bios lead product candidate, PHP-303, is a small molecule currently awaiting Phase II dose clinical study in the orphan disease Alpha1 anti-trypsin deficiency (AATD), with interim safety results expected by the end of 2023. Peak Bio has been successful at safely delivering a higher dose of PHP-303 in patients after single-ascending dose (SAD) and multiple-ascending dose (MAD) Phase I trials demonstrating dose-dependent pharmacokinetics and achieving preclinical recommended Phase II dose (RP2D).

What the company says about itself

Web research — not audited

What our web check found

[WEB-INTEL 2026-08-26] 3 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Peak Bio becoming a publicly traded company valued at $278 million." [https://globalgenes.org/raredaily/peak-bio-to-go-public-in-merger-with-ignyte-acquisition-spac/] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "a $25 million common stock PIPE" [https://globalgenes.org/raredaily/peak-bio-to-go-public-in-merger-with-ignyte-acquisition-spac/] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The deal is expected to be completed in Q3 2022." [https://lawstreetmedia.com/deals/peak-bio-and-ignyte-acquisition-corp-to-combine-in-278m-deal/] [WEB-INTEL 2026-08-26] 3 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Peak Bio becoming a publicly traded company valued at $278 million." [https://globalgenes.org/raredaily/peak-bio-to-go-public-in-merger-with-ignyte-acquisition-spac/] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "a $25 million common stock PIPE" [https://globalgenes.org/raredaily/peak-bio-to-go-public-in-merger-with-ignyte-acquisition-spac/] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The deal is expected to be completed in Q3 2022." [https://lawstreetmedia.com/deals/peak-bio-and-ignyte-acquisition-corp-to-combine-in-278m-deal/]

Source: company web presence · marketing claims are reported as claims, never merged into the filed figures above.

The deal it’s entering

Peak Bio is merging with Ignyte Acquisition Corp. (IGNY) currently marked Closed (deSPAC).

Headline equity value	—
PIPE	≈ $3M · unsourced

Structure per SEC accession(s) 0001193125-24-236786. How to read these numbers: headline vs effective valuation · what a definitive agreement commits

What exactly is being valued, and at what

Common questions

Is Peak Bio going public?

Peak Bio has an approved merger with the SPAC Ignyte Acquisition Corp. (IGNY). Deal status: Closed (deSPAC).

Does Peak Bio have revenue?

The filings we've parsed don't state a usable revenue figure yet; this profile is updated as new documents land.

Educational content, not investment advice.